Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
EXEL Stock Chart & Stats
$46.24
$0.17(0.50%)
At close: 4:00 PM EST
$46.24
$0.17(0.50%)
Day’s Range― - ―
52-Week Range$31.90 - $49.62
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.58M
Market Cap
$12.47B
Enterprise Value$10.35B
Total Cash (Recent Filing)$988.53M
Total Debt (Recent Filing)$176.46M
Price to Earnings (P/E)19.5
Beta0.88
Next Earnings
Feb 10, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding268,112,150
10 Day Avg. Volume2,737,979
30 Day Avg. Volume2,575,159
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.39
Price to Sales (P/S)4.54
P/FCF Ratio15.55
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue4.53
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda12.00
Forecast
1Y Price Target
$43.80Price Target Upside-5.28% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)2.9
Revenue Forecast (FY)$2.33B
Bulls Say, Bears Say
Bulls Say
Oncology Growth StrategyExelixis management outlined long-term plans to grow into a top 5 oncology powerhouse, building on its existing success with the Cabometyx franchise in the genitourinary and gastrointestinal space.
Pipeline InnovationExcitement is particularly high about the four antibody-drug-conjugate programs and the orally available SSTR2 agonist small molecule, which should allow Exelixis to become further entrenched in the neuroendocrine tumors market.
Revenue Growth PotentialZanzalintinib is expected to hold increasing responsibility for driving revenue growth, beginning with third-line metastatic colorectal cancer and later with non-clear cell renal cell carcinoma, pending positive data.
Bears Say
Adverse Event ConcernsThe 60% grade 3 and 4 treatment-related adverse event frequency is potentially burdensome for patients.
Clinical Trial ConcernsApproval for zanza+atezo in 4L+ mCRC is not guaranteed due to smaller than expected overall survival benefit.
Commercial RisksRisks include commercial risk with respect to Cabometyx (cabozantinib) and failure to generate favorable data from ongoing clinical programs, particularly those involving zanzalintinib.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $31.90 and its highest was $49.62 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $12.47B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Feb 10, 2026 which is in 44 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Nov 04, 2025. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.685 by $0.095.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.76.
How many shares outstanding does Exelixis have?
Exelixis has 268,112,150 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.78 in its last earnings report, beating expectations of $0.685. Following the earnings report the stock price went up 6.517%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.80 (-5.28% Downside)
$43.80 (-5.28% Downside)
Blogger Sentiment
Bullish
EXEL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.88%
12-Months-Change
Fundamentals
Return on Equity
30.56%
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
EXEL Company Deck
EXEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful market penetration of new treatments, particularly in the oncology segment. The advancement of zanzalintinib in clinical trials and its potential new indications were key positives. However, restructuring charges and potential regulatory delays posed challenges. Overall, the positive aspects outweigh the negatives, indicating a favorable outlook.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$43.80
▼(-5.28% Downside)
Technical Analysis
Ownership Overview
3.72% Insiders
24.55% Mutual Funds
25.33% Other Institutional Investors
17.66% Public Companies and Individual Investors